AUG 24, 2016
Cornea/External Disease, Refractive Mgmt/Intervention
Dublin-based Presbia PLC has acquired Neoptics AG, developer of a micro lens for presbyopia correction.
Both companies focus on small lens corneal implants for presbyopia. Presbia expects its Flexivue Microlens, a 3 mm diameter inlay placed in the non-dominant eye, will be FDA-approved in 2017. The Microlens has already received a CE mark for use in the European Economic Area. Switzerland-based Neoptics’ ICOLENS system is available outside the U.S.
"The acquisition of Neoptics' assets, including its patent portfolio, consolidates the principal intellectual property and ‘know-how' underpinning the use of an optically powered micro-lens for the correction of presbyopia (near-vision loss), a condition affecting 1.8 billion people globally,” said Todd Cooper, President and CEO of Presbia. “This consolidation of IP and know-how from Presbia and Neoptics has also created a patent protected platform to deploy our ‘micro-lens' technology into solutions for vision problems beyond presbyopia, significantly expanding our addressable market into the future."